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We have identiﬁed a new variant of human Stat5a, found at higher ratios to full-length Stat5a in invasive
ductal carcinoma versus contiguous normal tissue. The variant, missing exon 5, inhibits p21 and Bax pro-
duction and increases cell number. After prolactin stimulation, only full-length Stat5a interacts with the
vitamin D and retinoid X receptors, whereas only D5 Stat5a interacts with activating protein 1–2 and
speciﬁcity protein 1. Prolactin also oppositely regulates interaction of the two Stat5a forms with b-cate-
nin. We propose that a change in splicing leading to upregulation of this new isoform is a pathogenic
aspect of invasive ductal carcinoma.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction established tumors, has been proposed [8]. Having serendipitouslyThe signal transducer and activator of transcription (Stat) 5a is
activated in response to a wide variety of cytokines. Those acting
directly on mammary epithelium include growth hormone and
prolactin (PRL) [1]. Once activated, Stat5a homo- or hetero-dimer-
izes and enters the nucleus where it functions as a transcription
factor [2]. In the mammary gland, activation of Stat5a is important
to both growth and differentiation [3,4]. Particularly because of the
mediation of growth, the role of Stat5a in the development of breast
cancer has been examined, and is complex. For example, mammary
tumorigenesis is delayed when the Stat5a gene is deleted [5], sug-
gesting a tumor-promoting role for Stat5a. At the same time, higher
nuclear Stat5 activation is associated with a less invasive pheno-
type and a better prognosis [6,7]. Thus, a dual role for activated
Stat5a, in which Stat5a promotes tumor initiation, but is also
important for the maintenance of differentiation of moreidentiﬁed a new N-terminal splice variant during cloning of the ac-
cepted full length variety, we askedwhether the apparent duality of
Stat5a in breast cancer might result from the presence of this
previously unrecognized splice variant. The new variant of human
Stat5a, missing thirty amino acids of the N-terminus corresponding
to the whole of exon 5, was named D5 Stat5a. Compared to full
length (FL) Stat5a, this alternatively-spliced form interacts
differently with other transcription factors and Stat5a-responsive
promoters. Increased expression of D5 Stat5a results in increased
cell number. Furthermore,D5 Stat5a is expressed in invasive ductal
carcinoma at greater ratios to FL Stat5a than in contiguous histolog-
ically-normal tissue. These results suggest that D5 Stat5a plays a
role in tumor initiation, while FL Stat5a is likely more important
to maintenance of tissue differentiation.
2. Materials and methods
Additional experimental details can be found in the appropriate ﬁgure legends.
2.1. Cell culture
HEK 293, MCF-7, MCF-10a, MCF-12a, T47D, MDA MB468, HUVEC, U2OS, SaOS,
PC3 and DU145, were obtained from American Type Culture Collection (Manassus,
VA), where they were authenticated by short tandem repeat DNA proﬁling. Cells
were cultured in media and supplements from Invitrogen (Carlsbad, CA).
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Two pairs of primers were designed to amplify two fragments of the Stat5a cod-
ing sequence, an N-terminal fragment and a C-terminal fragment, and about 150 bp
of overlay. For the 50-terminal fragment, the forward and reverse primers were: 50-
GCT GCT CTC CGC TCC TTC CTG TAG TAA C-30 (S)/50-GCT CAT TGC TGC CAA CAC TGA
ACT G-30(A) and for the 30-terminal fragment, the forward and reverse primers
were: 50-AAT GAG AAC ACC CGC AAC GAG-30 (S) /CAA CAC GAC CGC TTC ACA
TTG-30(A). One more PCR reaction was designed to combine the two fragments
using 50-GAC ACG CGT ACC ATG GCG GGC TGG ATC CAG-30(S)/ 50-AAC GGT ACC A
TGA GAG GGA GCC TCT GGC AGA-30(A). The cleavage sites for Mlu I and KpnI
(shown in boldface) were designed to ligate the STAT5a cDNA forms into desired
plasmids.
2.3. Transient transfection and promoter constructs
For experiments examining promoter activation, dimerization, phosphoryla-
tion, and subcellular localization of D5 Stat5a versus FL Stat5a, transient transfec-
tions were performed using Lipofectamine™ 2000 (Invitrogen) a day after plating
when the cells were 90–95% conﬂuent. The cells were examined 48 h later. Controls
included luciferase unlinked to either form of Stat5a such that this could be used as
a measure of transfection efﬁciency. For the bioluminescence resonance energy
transfer (BRET) experiments, the signal generated by unlinked luciferase together
with unlinked green ﬂuorescent protein (GFP), was used as a measure of back-
ground randommolecular interactions. An artiﬁcial promoter containing 3 identical
Stat5 response elements linked to a Renilla luciferase (Rluc) reporter [9] and a
b-casein-luc plasmid, which contains 2.4 kb of the proximal b-casein promoter
[10], were generous gifts from Drs. Linda Schuler (Madison, WI) and Jeffrey Rosen
(Baylor, TX). To study p21 and Bax promotor activity, constructs containing the
full-length p21 [11] or Bax [12,13] promoter regions linked to a luciferase reporter
were used, as described previously [14]. To determine the potential differential
ability of FL and D5Stat5a to tetramerize, promoters with two identical Stat5 re-
sponse elements separated by 1–25 nucleotides linked to a luciferase reporter were
constructed (see diagram in supplementary data Fig. 1). These were co-transfected
with long form prolactin receptor (PRLR) and the FL Stat5a construct into HEK 293
cells and 24 h later were exposed to PRL for a further 24 h. After establishing the
optimal spacer length to achieve synergy between the two Stat5 response elements
in this system, the effect of D5 Stat5a and FL Stat5a on promoter activity with 1 and
2 GAS sites (the latter separated by the determined optimum) was determined
under the same conditions.
2.4. Dicer substrate small interfering RNA (DsiRNA) for knockdown of D5 Stat5a
Cells were transfected with 1 lg DsiRNA for D5Stat5a or the universal negative
control (IDT Technology, San Diego, CA). The custom DsiRNA D5Stat5a duplex
sequence was:
50-CACGCAGCUCCAGUGCAGCUCUCCG-30 (S)
50-CGGAGAGCUGCACUGGAGCUGCGUGGC-30(A)
Cells were collected 24 h after transfection and RNA/protein expression was
analyzed by RT-PCR using the D5 Stat5a-speciﬁc primers and Western blot using
the C-terminal antibody that recognizes both forms of the protein.
2.5. Bioluminescence resonance energy transfer
BRET analyses were performed as previously described [15] using vectors carry-
ing FL Stat5a orD5 Stat5a, the long form of the PRLR or Stat5b upstream of modiﬁed
green ﬂuorescent protein (GFP2) or Renilla luciferase (Rluc). Energy transfer was
deﬁned as the BRET ratio (Emission500nm–520nm  background500nm–520nm)/(Emis-
sion385nm–420nm  background385nm–420nm). Signals obtained from non-transfected
cells and co-transfected plasmids expressing unlinked Rluc and GFP2 were
considered background.
2.6. Viable cell number (MTS assay)
This assay, which measures reduction of MTS [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,innersalt] by mito-
chondria in viable cells, was performed under strict conditions, as previously
described [16].
2.7. Generation of FL and D5 Stat5a recombinant adenoviruses
Recombinant adenoviral vectors expressing either FL or D5 Stat5a were con-
structed according to the Stratagene (La Jolla, CA) protocol. Essentially, a replica-
tion-deﬁcient E1- and E2-deleted Ad5 vector, AdEasy, was used as a backbone.
This allowed for the addition of a hemagglutinin (HA) tag on the Stat5a molecules
and regulation of expression by a human cytomegalovirus promoter/enhancer. The
Stat5a cDNA sequences were ampliﬁed from a eukaryotic expression vector andsubcloned into a shuttle vector, pShuttle-IRES-GFP-1. The cDNA sequences were
then uploaded from the shuttle vector onto the adenovirus genome through homol-
ogous recombination. Once a recombinant was identiﬁed, bulk production used the
recombination-deﬁcient XL10-Gold strain. Puriﬁed Ad plasmid DNA was digested
with Pac I to expose its inverted terminal repeats, and then used to transfect AD293
cells (Stratagene) where deleted viral assembly genes are complemented. Titer in
plaque-forming units (p.f.u) was determined following infection of AD293 cells.
The multiplicity of infection (MOI) was deﬁned as the ratio of the number of p.f.u
used to the number of cells to be infected. To assess the efﬁciency of the adenovi-
rus-mediated gene transfer, cells were co-infected with AdlacZ and stained for
b-galactosidase.
2.8. Chromatin Immunoprecipitation Assay (ChIP Assay)
Cells were infected and treated as described in the ﬁgure legend. Human PRL
was puriﬁed from Escherichia coli as described previously [17]. Cross-linking was
performed with 1% formaldehyde in Dulbecco’s phosphate-buffered saline (DPBS)
at room temperature for 5–10 min. To arrest cross-linking, glycine was added di-
rectly to the medium to a ﬁnal concentration of 125 mM for 10 min, and the cells
were then rinsed twice with ice-cold DPBS. Cell extracts were harvested with lysis
buffer (0.5 ml/35 mm plate of 10 mM Tris–HCl, 1 nM EDTA, pH 8.0, 0.5% Nonidet P-
40, 1 mM phenylmethylsulfonyl ﬂuoride; 1 lg/ml aprotinin; 1 lg/ml leupeptin)
and frozen in liquid nitrogen. Lysates were transferred to 15-ml tubes containing
25 lm glass beads and the lysate/bead mixture was sonicated (Sonic dismembrana-
tor, Fisher Scientiﬁc, Pittsburg, PA) in ice (9 pulses of 20 s at a setting of 6 W), yield-
ing chromatin fragments of about 500 bp in size. After centrifugation at 14,000g for
4 min at 4 C, supernatants were collected. To provide a positive control (input),
200 ll of the supernatant was set aside. Each immunoprecipitation was performed
with 25 lg chromatin in RIPA buffer (140 mM NaCl; 1 mM EDTA; 10 mM Tris–
HCl; 1 mM phenylmethylsulfonylﬂuoride; 1% Triton X-100; 0.1% sodium dodecyl
sulfate; 0.1% Na-deoxycholate, pH 8). To reduce non-speciﬁc background, each
chromatin sample was pre-cleared with 60 ll of a suspension of protein A-Sephar-
ose, supplemented with 300 lg/ml sonicated salmon sperm DNA (Fermentas) and
1 mg/ml BSA, for 1 h at 4C on a rotating wheel. Chromatin complexes were immu-
noprecipitated for 16–18 h at 4 C while rotating with 10 lg primary antibody
(anti-HA, Santa Cruz, CA), or with a non-speciﬁc antibody to provide a negative con-
trol. Immune complexes were collected with 40 ll protein A-Sepharose (10 mg/ml
binding capacity), supplemented with 300 lg/ml sonicated salmon sperm DNA and
1 mg/ml BSA for 3 h at 4 C on a rotating wheel, followed by centrifugation at
14,000g for 30 s. Pellets were washed once with LiCl buffer (10 mM Tris–HCl, pH
8; 250 mM LiCl; 1 mM EDTA, pH 8; 0.5% Nonidet P-40; 0.5% Na-Deoxycholate),
and twice with TE buffer (10 mM Tris–HCl; 1 mM EDTA, pH 8). After standard ribo-
nuclease and proteinase K treatment, overnight at 37 C, cross-linking was reversed
by incubation for 6 h at 45 C. DNA was puriﬁed by phenol/chloroform extraction
and precipitated in the presence of 100 lg of glycogen per sample. PCR ampliﬁca-
tion was performed using primers speciﬁc for various regions of the b-casein
promoter (see ﬁgure for regions). The primers used were as follows:
primer 1:50-ggaatgacaaaggcgacattgccaccaacc-30(S)/50-gcatctatgttcatcaggggtatt
ggcata-30(A)
primer 2: 50-ctctaagctcatatttcttattccatgatt-30(S)/50-cagatatgaaggcaggataaagg
gtaaaat-30(A)
primer 3: 50-gattagtgtgactaaaaattgatgagcatt-30(S)/50-atatcatcctagatctatgaatg
aggggga-30(A)
primer 4: 50-agctcaaacttggtcagtttcattttaata-30(S)/50-aagcagttaatcgaggaggataga-
gaattc-30(A)
primer 5: 5-actgtcctccagtcattgtcttttgttatt-30(S)/50-atgacacactaattttgtgatttgaaat-
aa-30(A).
2.9. Processing of tumor tissues and quantitative real time polymerase chain reaction
(qRT-PCR)
Breast tissues were homogenized in TRIzol (100 mg/ml). RNA was extracted and
the quality determined by OD 260/280 nm (>1.8) by NanoDrop before conversion to
cDNA. SYBR Green qPCR was performed with an ABI Prism 7700 sequence detector
with normalization to b-actin. Primers, speciﬁc to FL or D5 Stat5a were: FL: 50-TGG
TCC GAG AAG CCA ACA-30(S)/50-AG GCT CTC CTG GTA CTG GAT-30(A). D5:50-GCA
GCT CCA GTG CAG CTC TC-30 (S)/50-CA AAC TGA GCT TGG ATC CTC-30 (A). Gel anal-
ysis of products demonstrated the speciﬁcity of these primers and qPCR demon-
strated equivalent efﬁciencies (Average Ct for FL primers was 17.20 and for D5
primers was 17.27). The amplicon product is 1044 bp for FL and 1034 bp for D5.
The D5 primers were also used for semi-quantitative PCR.
2.10. Gel electrophoresis and general Western blotting
Cell lysates were prepared in the presence of protease and phosphatase inhib-
itors (Promega Madison, WI). In order to obtain well-separated bands, electropho-
resis occurred for 4–5 h in 7 cm 9% SDS minigels at 100 V. Western blotting of
multiple cell lines was with an antibody to the C-terminus of Stat5a (L20) that
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(N12) was used to verify the purity of nuclear and cytoplasmic fractions. For phos-
phorylation, cells were transfected with plasmids to overexpress either FL Stat5a or
the D5 Stat5a-GFP construct. Immunoprecipitation was with either anti-Stat5 (836)
or anti-GFP (5384) and immunoblotting was with anti-phosphotyrosine (508) or
anti-GFP. No immunoprecipitation occurred prior to blotting with anti-p21(397)
or anti-BAX (625102). Localization was with an appropriate species-speciﬁc perox-
idase-linked second antibody. All antibodies were from Santa Cruz Biotechnology
except for anti-BAX (Biolegend, San Diego, CA). For each antibody, the catalogue
number is provided in parentheses. Quantiﬁcation of Western blots used photoshop
image analysis software.
2.11. Transcription factor interactions
TF–TF Array (Panomics/Affymetrix, Santa Clara, CA): Cells were treated as de-
scribed in the ﬁgure legend. Nuclear extracts were prepared (Active Motif, Carlsbad,
CA) and incubated with biotin-labeled, double-stranded oligonucleotide probes at
15 C for 30 min. An antibody against the C-terminus of Stat5a that equally recog-
nizes both forms was used to bind FL and D5 Stat5a and any associated transcrip-
tion factor, along with the corresponding labeled probes. The oligo/protein/
antibody complexes were precipitated using avidin-Dynabeads, eluted from the
beads and hybridized with the TF–TF interaction array membrane (Array I, pre-
spotted with 54 cis-elements) overnight. The hybridized spots on the membrane
were incubated in peroxidase-labeled second antibody.
Co-immunoprecipitations: Cells were transfected with 3 lg plasmids (FL Sta-
t5a-GFP, D5STAT5a-GFP or PCDNA 3.1 empty plasmid as control). Anti-GFP (2 lg)
was added to 200 lg total cell lysate, and 20ug total cell lysate with control plasmid
was used as control. Anti-Sp1(59G) and -RXR (D20) were from SantaCruz and anti-
b-catenin was from BD Transduction (San Jose, CA).
2.12. Patient samples
Tumors and adjacent normal regions were obtained at surgery, identiﬁed by a
pathologist as early invasive ductal carcinoma with no lymph node positivity, and
forwarded as anonymous samples by institutions working as part of the National
Cancer Institute’s Cooperative Human Tissue Network (CHTN) http://
www.chtn.nci.nih.gov/human-subjects/. Each branch of the network obtains writ-
ten informed patient consent for the banking and distribution of samples for
research. Most samples in this study were obtained from the Midwestern Division
of CHTN and their statement about informed consent can be found at https://htrn.
osu.edu/Services/TissueProcurement/Pages/default.aspx. Samples are distributed
by CHTN branches after coding for anonymity. Use of anonymous patient samples
in this study was approved by the University of California, Riverside, Institutional
Review Board.
2.13. Statistical analyses
All statements are based on replicated experiments (a minimum of three times)
except for the surveys of cell lines designed to determine the simple presence or
absence of either D5 Stat5a mRNA or protein. For quantitative data, analysis
was by ANOVA with post-tests and, where applicable, corrections for multiple
comparisons.
3. Results
3.1. A new variant of human Stat5a
Stat5a cDNA was ampliﬁed by PCR. Unexpectedly, agarose
electrophoresis showed two PCR products: one corresponded to
FL Stat5a, but the other was shorter (result for U2OS osteosarcoma
cells shown in Fig. 1A). Sequence analysis showed that the smaller
fragment was shorter by 90 nucleotides and missing the region
corresponding to exon 5 (Fig. 1B). Exon 5 codes for a small part
of the N-terminal region (Fig. 1C). Modelling using the Geno3D
program (http://geno3d-pbil.ibcp.fr) predicted an overall very sim-
ilar structure in which the major difference was the absence of a
small a helix, indicated by the white oval (Fig. 1D).
3.2. Delta 5 Stat5a is widely expressed
To rule out the possibility that the shorter product of Stat5a was
due to an error during cloning or was speciﬁc to aberrant splicing
in one cell line, multiple cell types were examined for potential
expression of the variant using primers speciﬁc for the D5 form.The speciﬁcity of the primers is illustrated in Fig. 2A. The additional
human cell lines examined were a second osteosarcoma line
(SaOS), embryonic kidney (HEK 293), vascular endothelial (HU-
VEC), prostate cancer (PC3, DU145), and normal and cancerous
breast epithelial (MCF-10a, MCF-12a, MCF-7, T47D) cells. Expres-
sion was evident in each of these cell types at the mRNA level (a
selection is shown in Fig. 2B). It is apparent therefore that expres-
sion is not an oddity of a particular cell line, but occurs in cell lines
considered relatively normal, as well as those that are cancerous.
No equivalent form of Stat5b could be detected (negative data
not shown).
Because some mRNA splice variants are not expressed as pro-
teins, the next question was whether D5 Stat5a was expressed at
the protein level. Because the protein size is not very different from
the FL Stat5a (only 30 amino acids in a 90 kDa protein), several dif-
ferent electrophoresis conditions were tried to determine how to
adequately separate the two forms. The Western blot in Fig. 2C
shows electrophoretic separation of the proteins and a sampling
of the cell lines, all of which expressed a protein of the correct size,
as well as the mRNA. To demonstrate that the lower protein band
was indeed the D5 Stat5a variant, we used a DsiRNA. This was
designed to target part of exon 4 and part of exon 6 and so was
speciﬁc to the D5 Stat5a splice form. Transfection with the DsiRNA
knocked down expression at the mRNA and protein levels (Fig. 2D).
An analysis of ﬁve separate HUVEC cultures showed that D5 Stat5a
constituted 38.4 ± 6.75% (SD) of total Stat5a. In other words, FL
Stat5a was present at about a 2:1 ratio with D5 Stat5a in this
low passage number, normal cell line (Fig. 2E). Similar analyses
of T47D cells and DU145 cells showed more variable results. Test-
ing of ﬁve independent cultures of T47D cells on one occasion gave
a ratio of 1.15 ± 0.17 SD, while similar analysis of DU145 cells gave
a ratio of 0.55 ± 0.23 SD. However greater variability than this in
the ratio in cancerous cell lines is illustrated by the difference be-
tween the number for T47D and DU145 cells and the ratios shown
in Fig. 2C. The cause of the variability from one occasion to another
is unknown, but could be related to cell density at the time of
sampling, growth curve kinetics, or passage number. Without a
constant ratio, no conclusions can be drawn about ratios in
relatively normal versus cancerous cell lines.
3.3. Delta 5 Stat5a homodimerizes and heterodimerizes with FL Stat5a/
b and the PRLR
FL Stat5a binds to a tyrosine-phosphorylated transmembrane
receptor and, after its own phosphorylation by a receptor-
associated tyrosine kinase, then dimerizes with itself or Stat5b
before translocation to the nucleus [8]. Because of the similarity
in molecular weight between Stat5b and D5 Stat5a and the
absence of any speciﬁc anti-phospho Stat5a antibody, we used a
GFP2-tagged variety to determine whether D5 Stat5a was phos-
phorylated. The GFP2-tagged D5 Stat5a runs at a molecular
weight of 126 kDa and separates nicely from other forms of Stat5.
Fig. 3A shows phosphorylation of both FL and D5 Stat5a forms in
response to serum in MCF7 cells. In these early studies of general
function, serum stimulation was used in order to determine the
likely general level of activation of this new form of Stat5a under
most conditions. To determine whether nuclear translocation oc-
curred, HEK293 cells were transiently transfected with a plasmid
carrying D5 Stat5a-GFP2 cDNA. At the level of transfection em-
ployed, GFP-labeled D5 Stat5a was not very obvious when dis-
persed in the cytosol. However, when concentrated by nuclear
translocation, the ﬂuorescence becomes obvious. Fig. 3B shows
concentrated nuclear ﬂuorescence in a successfully transfected
cell. No nuclear translocation was observed in serum-starved
cells (not shown). Nuclear translocation was further substanti-
ated by producing nuclear and cytoplasmic fractions from T47D
Fig. 1. A new variant of Stat5a missing the sequence corresponding to exon 5. A: an ethidium bromide stained agarose gel illustrating two cDNA bands corresponding to full
length (FL) and D5 Stat5a (D5), in this case derived from U2OS human osteosarcoma cells. B: Sequence alignment of the region of deletion between FL and D5 Stat5a. Broken
line represents the missed nucleotides. C: Cartoon showing the missing portion of the Stat5a protein. TFD, tetramer forming domain; CCD, coiled coil domain; DBD, DNA
binding domain; LD, linker domain; SH2, src homology domain 2; TAD, transactivation domain. The amino acid sequence of exon 5 is shown, as is the tyrosine
phosphorylation site essential for dimerization. D: model of D5 Stat5a structure compared to FL Stat5a. Oval on FL model shows missing region, which is an a-helix shown in
yellow at the N-terminus.
Fig. 2. Expression of D5 Stat5a at mRNA and Protein Level. A: Ethidium bromide
stained gel showing the speciﬁcity of the primers for FL and D5 Stat5a. Lane 1,
primers speciﬁc to FL used with plasmid for D5; lane 2, primers speciﬁc for FL used
with plasmid for FL(amplicon of 1044 bp); lane 3, primers speciﬁc for D5 used with
plasmid for FL; lane 4, primers speciﬁc for D5 used with plasmid for D5 (amplicon
of 1034 bp). B: ethidium bromide stained gel showing D5 Stat5a-speciﬁc amplicons
produced from cDNA in each cell type. C: Western blot showing both FL and D5
Stat5a protein in mostly the same cell lines as shown in B. The antibody used was
against the C-terminus of Stat5a and therefore recognized both FL and D5 Stat5a
protein. D: Effect of DsiRNA knockdown of D5 Stat5a on mRNA (upper panel) and
protein (lowest panel). 5  105 cells were seeded in 35 mm wells. The next day,
cells were transfected with 1 lg DsiRNA or control. Cells were collected 24 h after
transfection and RNA/protein expression was analyzed by RT-PCR andWestern blot.
E: Western blot of FL and D5 Stat5a from ﬁve HUVEC cultures.
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endogenous rather than transfected forms. TATA binding protein
was used as a marker for purity of the nuclear and cytoplasmic
fractions (Fig. 3C). To determine the binding capabilities of D5
Stat5a, BRET analysis was performed. In this technique, the two
molecules being examined for binding are tagged with either
luciferase or GFP2. With close approximation (within 100 Å) and
upon addition of cell permeant luciferase substrate, luminescence
energy is transferred to GFP2 and then emitted at 510 nm. A BRET
ratio greater than the control (GFP2N1/RluN1) shows binding.
Thus, D5 Stat5a behaved like FL Stat5a in terms of its ability to
interact with the long form of the PRLR, homodimerize, and hete-
rodimerize with both FL Stat5a and Stat5b (Fig. 3D).
3.4. Delta 5 Stat5a binds to Stat5 response elements (GAS sites)
TodeterminewhetherD5 Stat5a competedwith FL for binding at
response elements, we ﬁrst used an artiﬁcial promoter consisting of
multiple response elements linked to a luciferase reporter. This pro-
moter construct was transiently transfected into HEK 293 cells
along with expression vectors for FL and increasing amounts of
D5 Stat5a. In addition to affording high efﬁciency transfection,
HEK 293 cells were chosen since analyses showed a fairly stable ra-
tio of approximately equal amounts of the two forms under normal
circumstances. This allowed for a more straightforward analysis of
response to increased expression of one form versus the other. Gi-
ven that the plasmids only differed by 90 nucleotides, it is likely that
expression levels were very similar. Certainly, under circumstances
where we could distinguish the transfected from endogenous by
using GFP-tagged constructs (see later ﬁgures), this was the case.
Fig. 3. Phosphorylation, nuclear translocation and Initial Protein–Protein Interactions. A: Western blot of immunoprecipitated protein extracts showing tyrosine
phosphorylated (pY) FL and GFP-tagged D5 Stat5a from MCF7 cells. Lanes 1 and 2 show endogenous Stat5, lanes 3 and 4 endogenous plus additionally expressed transfected
FL Stat5a, and lanes 5 and 6 the higher molecular weight transfected GFP-tagged D5 Stat5a. The lower panel shows the anti-GFP blot from the same lysate. B: confocal image
(Zeiss 510) shows nuclear translocation of GFP2-tagged D5 Stat5a. D5 Stat5a-GFP2 was transiently expressed in HEK 293 Cells (in the presence of 10% FBS, which contains
factors that can activate Stat5a). Fluorescence was examined 72 h after transfection in a non-synchronized culture. The photograph is a merge of the ﬂuorescence and phase
contrast images. C: Nuclear translocation of endogenous FL and D5 Stat5a in T47D cells. Nuclear and cytoplasmic fractions were produced using the NE-PER kit (Pierce,
ThermoFisher, Rockford, IL) after a 10 min incubation in PRL and then processed for Western blotting. TBP, TATA binding protein. D: Cultured HEK 293 cells were co-
transfected with appropriate plasmids and a BRET2 assay was performed. The higher the BRET ratio, the greater the amount of energy transferred as a result of proximity. D5
Stat5a hetero-dimerized with FL Stat5a and Stat5b (compare D5/FLA and D5/FLB with FLA/FLB), and homo-dimerized with itself (D5/D5). It was also able to associate with
the PRL receptor (D5/PRLR). *P < 0.05 versus GFP2N1/RlucN1 (negative control testing random interactions between luciferase and GFP2).
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cells by using the GFP2N1 plasmid. When cells were incubated in
serum and only the FL Stat5awas co-transfected, the luciferase con-
struct was highly expressed. When tested for its ability to activate
this artiﬁcial promoter, D5 Stat5a had only about 10% the activity
of FL Stat5a (data not illustrated). However, when titrated against
FL Stat5a, co-transfection with only one tenth the amount of D5
Stat5a construct reduced promoter activity in response to FL Stat5a
24-fold. Increasing amounts of D5 Stat5a showed a dose-related
further decrease (Fig. 4A).
In order to use a more biologically-relevant promoter, a
2.4 kb b-casein promoter upstream of a luciferase reporter
(b-casein-luc) was used. Also co-transfected was a plasmid coding
for the long form of the PRLR so that we could examine the
response to a speciﬁc stimulus over and above the mixture of
stimuli present in serum. In these cells growing in serum-supple-
mented medium and stimulated with PRL, increased expression
of FL Stat5a induced the b-casein-luc promoter compared to con-
trol, whereas increased expression of D5 Stat5a inhibited promoter
activity (Fig. 4B). In cells co-transfected with a ﬁxed amount of FL
Stat5a plus increasing amounts of D5 Stat5a, D5 Stat5a acted as a
dominant negative, although the degree of effect was not as great
as for the artiﬁcial promoter.
In order to examine the effect of D5 Stat5a on endogenous
expression of the b-casein gene, T47D breast cancer cells were in-
fected with adenovirus carrying FL or D5 Stat5a cDNA. Infection
with FL adenovirus tripled b-casein expression in response to
PRL, whereas D5 Stat5a had no effect (Fig. 4C). Nevertheless, D5
Stat5a reduced FL-induced b-casein expression such that one ﬁfth
the amount of D5 Stat5a virus brought levels induced by FL Stat5a
down to control values.With the novel variant described here, the alteration in struc-
ture is the absence of a small alpha helix. We therefore considered
the possibility that this would affect the ability of D5 Stat5a to
form tetrameric complexes [18]. To be sure we had a system in
which we could demonstrate the advantage of tetramerization
with the FL Stat5a, we titrated the number of residues between
two Stat5 response elements linked to a luciferase reporter to be
sure that we had the optimal distance for maximal activity
(Supplementary Fig. 1). The optimal number of residues was seven
(Supplementary Fig. 2). We then compared responses with one
versus two optimally-spaced (7 residues apart) Stat5 response ele-
ments. With no enhancement due to tetramerization, one would
expect double the activity with two versus one Stat5 response ele-
ment. With enhancement, one would expect a result greater than
double. Fig. 4D shows the result for both FL and D5 Stat5a. With
FL Stat5a, two Stat5 response elements gave a result that was
3.5-fold the result with 1. However, even though the response
was much reduced with D5 Stat5a, two Stat5 response elements
still gave a result that was 3.5-fold the result with 1. There was
therefore no demonstrable effect on the ability of D5 Stat5a to
tetramerize.
3.5. Delta 5 Stat5a and FL Stat5a show differences in binding to regions
of the b-casein promoter
The differences in degree of effect when titrating D5 Stat5a
against FL between the artiﬁcial promoter and the 2.4 kb b-casein
promoter or endogenous b-casein gene could have been the result
of differences in stimulus or possibly that FL andD5 Stat5a had dif-
ferent relative afﬁnities for different Stat5 response elements in the
b-casein promoter. To test the latter possibility, T47D cells were
Fig. 4. Competition at Stat5 Response Elements and Dominant Negative effect of D5 Stat5a on b-casein gene promoter and expression. A: HEK 293 cells were transiently
co-transfected with a multiple response element-luc reporter and constructs containing FL and/or D5 Stat5a cDNA, and incubated in serum. B: HEK 293 cells were transiently
co-transfected with a b-casein promoter-luciferase construct and constructs containing FL and/or D5 Stat5a cDNA. In this case, all cells were simultaneously transfected with
a long form PRLR construct. Relative light units (RLU) were measured 24 h after incubation in 1 lg/mL PRL. For each experiment, equal amounts of total DNA were transfected
for each group. C: T47D cells were infected with an adenovirus (Adv) carrying FL or D5 Stat5a cDNA at MOI 30 for 2 h. After 48 h, regular and real time RT-PCR was performed
to detect b-casein mRNA, normalized to b-actin mRNA. D: HEK 293 cells were transiently co-transfected with an artiﬁcial promoter containing 1 or 2 Stat 5 response elements
(sequence in supplementary Fig. 1) linked to a luciferase reporter, FL or D5 Stat5a, and long form PRLR. After 24 h, PRL (1 lg/ml) was added for a further 24 h. **p < 0.01,
compared to Con; #p < 0.05, ##p < 0.01, compared to FL.
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with an HA sequence and subjected to ChIP analysis. The relative
amount of b-casein promoter DNA associated with the anti-HA
immunoprecipitated complexes was determined by PCR. Five pairs
of primers (Fig. 5A) were designed to amplify regions containing
putative/proven Stat5 response element sequences in the pro-
moter. In Fig. 5B, the input columns show strong signals for each
primer set. Neither FL nor D5 Stat5a bound to the region covered
by primer set 5. However, FL Stat5a bound to the sequences ampli-
ﬁed by each of the other sets of primers. By contrast, no signal was
obtained for primer sets 1 and 2 whenD5 Stat5a was used. This re-
sult demonstrates that the two forms of Stat5a differentially distin-
guish among Stat5a binding sites, suggesting differential effects on
gene expression.
3.6. Delta 5 Stat5a differs from FL Stat5a in its binding to other
transcription factors
The three-dimensional model would predict very little if any ef-
fect of the deletion of exon 5 on the ability to bind DNA. Selectivity
for different Stat5 binding sites might therefore result from inter-
action with other transcription factors. A blast search using the
sequence of the helix missing in the D5 form, showed the greatest
identity (53%) to an A blade region of the WD40 domain of b-trans-
ducin (b-TrCP1) [19]. b-TrCP1 is a highly conserved protein that
controls the stability of proteins involved in transcription [19].
We therefore used an array to probe the interaction between FL
or D5 Stat5a and 54 other transcription factors in T47D breast can-
cer cells. Even though both forms of Stat5a are present in T47D
cells, infection was used to enhance expression of one form over
the other so that potential differences in their interactions could
be observed. Data presented in Table 1 show that D5 Stat5a inter-
acts with mostly different transcription factors than FL Stat5a. Thismethod cannot be considered quantitative since the oligonucleo-
tide probes cannot be assumed to have equal efﬁciency, and on
the array some spots saturate before others have developed;
therefore interactions can only be recorded as positive. Both FL
and D5 Stat5a interacted with activating protein-2 (AP-2) and
the early growth response protein (EGR). For the other 10 positive
spots, each only bound either FL or D5 Stat5a.
Three transcription factors/interacting proteins were further
explored by co-immunoprecipitation (Fig. 5C). In T47D cells, it is
clear that an interaction with RXR is speciﬁc to FL Stat5a and an
interaction with Sp1 is speciﬁc to D5 Stat5a (quantiﬁed in
Fig. 5D). PRL stimulation of the cells dissociated the complex be-
tween RXR and FL Stat5a since the intensity of the band decreased
as a function of time of incubation. By contrast, there was no clear
dependence of Sp1 binding to D5 Stat5a on the presence of PRL.
Since the missing portion in D5 Stat5a resembled part of a
protein that binds b-catenin, b-TrCP1, we also examined the possi-
bility that b-catenin bound differentially to the Stat5a forms.
However, both forms bound b-catenin. Interestingly though, PRL
undid the interaction of b-catenin with D5 Stat5a and promoted
the interaction of b-catenin with FL Stat5a. In MCF7 cells, less
distinct (perhaps due to a lower expression of PRL receptors), but
generally similar patterns were observed for b-catenin.
Thus, absence of the thirty amino acids corresponding to exon 5
has a major effect on complex formation with other transcription
factors, although nuances are present in different cell lines.
3.7. Cell number-related effects
Given the differential interaction with other transcription fac-
tors, we asked whether D5 Stat5a had a differential effect on two
Stat5a-responsive promoters, one related to cell cycle inhibition
and the other to apoptosis. Overexpression of both forms of Stat5a
Fig. 5. DNA and other transcription factor binding properties of D5 and FL Stat5a. Cultured T47D cells were infected with adenovirus carrying FL or D5 Stat5a cDNA tagged
with HA (at the C-terminus) at MOI 30 for 2 h. Forty-eight hours post-infection, cells were exposed to PRL for 10 min. Cross-linking was performed and 9.4 Kb of the b-casein
promoter was used as the target. A: Five pairs of primers (primers 1, 2, 3, 4 and 5) were used to amplify regions containing different predicted Stat5 binding sites indicated by
vertical bars. B: The samples were immunoprecipitated by an antibody against HA. Positive and negative controls are indicated as Input and IgG, respectively. C:
Co-immunoprecipitation using GFP-tagged versions of D5 Stat5a and FL Stat5a as a function of time of incubation in 100 ng/ml PRL. Immunoprecipitation was with anti-GFP,
followed by blotting with anti-GFP, b-catenin, RXR and Sp1. Grouped Westerns are from the same cell lysate for which the associated GFP staining is serving as loading
control. D: Quantiﬁcation of unstimulated interaction with Sp1 and RXR with FL and D5 Stat5a from multiple lysates. C, control. Results were normalized to the maximal
interaction in each case, which was given the value 100. *p < 0.001.
Table 1
Transcription factors interacting with FL and/or D5 Stat5a.
AP2 EGR CBF NF1 VDR RXR Stat3 NFjB MRE AP1-2 Sp1 TR
FL + + + + + + +
D5 + + + + + + +
T47D cells were infected with adenovirus carrying FL or D5 Stat5a cDNA. Ten
minutes prior to nuclear extraction, the cells were incubated in the presence of PRL
(500 ng/ml) to stimulate a Stat5-mediated response. Nuclear extracts were pro-
cessed as described inmethods and FL orD5 Stat5a-binding partners were identiﬁed
using a TF–TF membrane array pre-spotted with 54 cis-elements in duplicate
overnight. Results were replicated on three separate occasions. AP-1 = Fos, FosB,
Fra1, Fra2, Jun, JunB; AP-2, Acting enhancer binding protein 2; CBF, CAAT box
general; EGR, early growth response; NF-1, NF-1 nuclear factor 1; RXR, retinoid X
receptor; VDR, vitamin D receptor; Stat3, Signal Transducer and activator of tran-
scription-3; SP1, Sp1 transcription factor; NFkB, nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1; TR, thyroid hormone receptor; MRE, which
means that a metal response factor interacted.
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more efﬁcacious, essentially eliminating activity at both the p21
and Bax promoters (Fig. 6A). Corresponding effects on protein were
also observed (insets), and similar results were observed in T47D
cells (data not shown). To test whether this translated to an effect
on cell number, a variety of cells was infected at less than 50% con-
ﬂuency and incubated for 7 days in medium containing serum, and
in one case in the absence or presence of PRL. The outcome varied
in degree with cell line; in some instances, FL Stat5a had no effect
and in others, it increased cell number. However, in all cases D5
Stat5a increased cell number and always more than FL Stat5a.
Furthermore, PRL ampliﬁed the effect of increased expression of
D5 Stat5a (Fig. 6B). Because each form of Stat5a associated with
b-catenin, we also examined the effect of increased expression of
each form on levels of b-catenin and its membrane-binding part-
ner, E-cadherin. As shown in Fig. 6C, increased expression of both
forms of Stat5a increased protein levels of E-cadherin, but only
D5 Stat5a also increased b-catenin.3.8. Higher expression of D5 Stat5a was detected in breast cancer
tissue
Overexpression can produce anomalous results and effects in
cell lines, even if they had constant ratios of the two forms, may
not be representative of primary tumors. We therefore sought to
determine the expression of D5 Stat5a and FL Stat5a in patient
samples. Samples were obtained from regions of invasive ductal
carcinoma and from adjacent histologically-normal tissue. Results
of qRT-PCR are shown in Fig. 7. The relative level of mRNA for each
form in the two regions is presented for each patient. This is con-
verted to a ratio in Table 2; the ratio of D5 Stat5a to FL Stat5a
was always higher in the cancerous region, although the magni-
tude of difference varied considerably. The difference between
the ratios in normal versus cancerous tissue was signiﬁcant with
a p value = 0.007. With one exception, the ratio was either equal
or showed greater amounts of FL Stat5a in the histologically-nor-
mal tissue.4. Discussion
4.1. Why has D5 Stat5a not been previously observed?
Cloning of Stat5a from a human cell line has uncovered a novel
splice variant widely expressed in both normal and cancerous hu-
man epithelial cell lines, including those of the endothelium,
embryonic kidney, breast and prostate; this variant is also present
in osteosarcoma cell lines. Delta 5 Stat5a is therefore not an aber-
ration particular to cancerous cells, even though its production is
clearly increased in one or more cell type in primary human breast
cancer tissue. Delta5 only differs from FL Stat5a by 30 amino acids,
or 3.8% of the total mass. This likely explains its lack of previous
discovery. For example, since FL Stat5a and D5 Stat5a are so close
in size, it is likely that they were not resolved on previous Western
blots. Similarly, since 96% of the sequence is identical, RTPCR
Fig. 6. Effect of increased expression of Stat5a and D5 Stat5a on p21, Bax, b-catenin, E-cadherin and cell number. (A) MCF-7 cells were transiently transfected with expression
and promoter–reporter constructs. Results (luciferase activity) are normalized to the value in the control (C) transfections. Insets are Western blots that were all run on the
same gel, were processed for Western blotting and presentation together before rearrangement to display in the same order as the rest of the ﬁgure. (B) MCF7, MDA-MB 468,
T47D, and PC3 cells were infected with adenovirus carrying D5 or FL Stat5a cDNA at MOI 30 for 2 h and relative viable cell number was assayed 7 days later. For PC3 cells,
some cells were also stimulated with PRL. For T47D cells, actual cell numbers are presented as an extra control for possible non-speciﬁc effects of infection on the MTS assay.
n = 16 for each replicate. *p < 0.01, **p < 0.02, ***p < 0.005, ****p < 0.0001 versus control. C: Western blot from the T47D cells.
Fig. 7. Expression of D5 and FL Stat5a mRNA in Invasive Ductal Carcinoma and
Histologically-Normal Adjacent Breast Tissue. Results are shown as the relative
amount of mRNA (determined by qRT-PCR with normalization to b-actin) for each
form in the normal and cancerous region. Paired samples from 14 patients were
analyzed. The resultant ratios of the forms can be found in Table 2.
Table 2
D5 Stat5a to FL Stat5a mRNA expression ratio in 14 patients.
Patient Normal D5:FL Cancer D5:FL Fold Cancer v normal
1 3.3 15.3 4.64
2 0.14 67.5 4.82
3 1.3 2.2 1.7
4 0.01 4.35 435
5 1.31 24.03 18.34
6 0.53 4.16 7.85
7 0.28 49.35 176
8 1.25 4.12 3.3
9 0.57 18.16 31.86
10 0.55 4.89 8.9
11 0.4 9.06 22.6
12 0.73 12.35 16.9
13 0.88 2.27 2.58
14 0.74 3.61 4.88
Mean 0.86 15.8 52.8
Pre-ratio values for 10 of these patients can be found in Fig. 7. The ratio in the
cancer tissue is different from the ratio in the normal tissue with a p value of 0.007.
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have been observed in protocols using anti-pan Stat5 antibodies,
it is likely that the slightly smaller band was assumed to be Stat5b.
Moving forward, with the correct choice of primers and electro-
phoresis conditions, each form can be separately analyzed by
qRT-PCR, and Western blot. Unfortunately, since the alternate
splicing does not cause a frame shift and there is no major change
in predicted structure, speciﬁc antibodies to D5 Stat5a cannot be
produced. This precludes an immunohistochemical analysis
comparing the level of expression and nuclear localization of both
forms in breast cancer tissue.
4.2. Differential promoter activities
To determine the cellular consequence of increased expression
of D5 Stat5a, we examined its ability to behave like FL Stat5a. This
included the ability to bind to a suitable receptor, become phos-
phorylated, homo-dimerize, hetero-dimerize with FL Stat5a orStat5b, and translocate into the nucleus. In all of these aspects,
D5 Stat5a behaved like FL Stat5a. However, when tested for its
ability to activate an artiﬁcial promoter, it had 10% the activity of
FL. Moreover, when titrated against FL, D5 Stat5a acted as a dom-
inant negative. Dominant negative activity has been described for
other variants [20–22]. However, these variants have not been
found in mammary gland [23], despite speciﬁc searching. All other
variants of Stat5a are signiﬁcantly smaller and are missing part of
the C-terminus. In our Western analysis of D5 Stat5a, we used an
antibody against the C-terminus and hence would not have identi-
ﬁed these forms. Moreover, DsiRNA speciﬁc to D5 Stat5a knocked
down the D5 Stat5a band on a Western blot.4.3. Interaction with different Stat5 response elements
Dominant negative activity was also observed with 2.4 kb of the
b-casein promoter in a transfected system, as well as with the
endogenous b-casein promoter in breast cancer cells, although
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more complex and natural promoter compared to the artiﬁcial pro-
moter. One possible explanation for this was that D5 was not able
to compete with FL Stat5a at all of the response elements in the
natural promoter. Analysis by ChIP assay showed that this was in-
deed the case for the complete endogenous promoter since only FL
Stat5a bound to the regions covered by primer sets 1 and 2.
However, this did not explain the difference between the artiﬁcial
promoter and the 2.4 kb promoter since the 2.4 kb promoter only
contained the region covered by primer sets 4 and 5, where both
forms of Stat5a behaved similarly. This could have been related
to different cell systems, different stimuli, different sequences of
Stat5 response elements, or different interactions with other tran-
scription factors. Analysis of the Stat5 response element sequences
also showed that one of the two elements covered by primer set 2
was identical to the element covered by primer set 4, and yet D5
Stat5a bound to region 4 and not to region 2. Differential binding
could therefore not be explained by differences in the response ele-
ment sequences. The lack of binding by either form to region 5 in
the endogenous promoter was unexpected since this contained a
sequence identical to that used in the artiﬁcial promoter. The rea-
son for this is unknown, but could conceivably be related to the HA
tag, even though this was C-terminal and away from the DNA bind-
ing site, or to the speciﬁcs of the cell line used in which this site
could be masked by binding of other proteins. These proteins could
include the B cell lymphoma 6 protein, which binds similar se-
quences [24], or proteins that bind adjacent sites, such as brachy-
ury, a transcription factor expressed during the epithelial to
mesenchymal transition [25,26].
4.4. Interaction with other transcription factors
Since the details of the Stat5 response element sequences were
not the key, we considered differences resulting from association
with other transcription factors. With an array allowing measure-
ment of an interaction between either FL orD5 Stat5a and 54 other
transcription factors, we observed speciﬁc interaction of one or
other form with 12 transcription factors/complexes in PRL-stimu-
lated T47D breast cancer cells. Of these 12, only activating protein
2 (AP-2) and the early growth response (EGR) protein were
common to both forms of Stat5a. Of the remaining 10 transcription
factors, FL bound to CAAT box general (CBF), nuclear factor-1 (NF-
1), the vitamin D receptor (VDR-DR3), retinoid X receptor (RXR-
DR1) and signal transducer and activator of transcription 3 (Stat3).
By contrast, D5 Stat5a bound to activating protein-1-2 (AP-1-2)
but not AP-1-1, nuclear factor kappa light chain enhancer of
activated B-cells (NFjB), metal response factor (MRF), thyroid
hormone receptor (TR) and speciﬁc protein-1 (SP-1).
Further analysis of RXR and Sp1 by co-immunoprecipitation
conﬁrmed the array results and, in the case of RXR, demonstrated
a dependence on PRL. It will take considerable work to determine
the functional consequences of the multiple and differentially-
regulated interactions. However, with that caveat stated, and
knowing that the D5 form has increased expression in invasive
breast cancer, it is tempting to speculate that a heterodimer
between FL Stat5a and the VDR [27] or RXR [28] may be important
for maintaining differentiation, whereas an interaction between
D5 Stat5a and some component of the AP-1 complex may be
important in tumor formation [29–33].
What is clear from these results is that the two forms of Stat5a
interact differently with other transcription factors. The region of
Stat5 traditionally considered to be important for protein–protein
interactions is the coiled coil domain [34], whereas more recent
data [e.g. 35] and the data herein show an important role for the
N-terminal domain. Further, our data show a speciﬁc role for a
small N-terminal a helix.4.5. Effects on cell number
Inhibition of p21 and Bax expression would be expected to
reduce cell cycle control at the G0/G1 checkpoint [36] and to de-
crease apoptosis [37], respectively, both effects likely contributing
to the increased cell number when D5 Stat5a expression was in-
creased in cancer cells. Also, without this checkpoint control,
damaged DNA could be replicated [36], thereby increasing the like-
lihood of oncogenic change with increased D5 Stat5a. The increase
in cell number from increased expression ofD5 Stat5a was variable
among cell lines and not absolutely speciﬁc to the D5 form,
although the D5 form always increased cell number, whereas the
FL Stat5a did not. The increase in cell number with D5 Stat5a ran-
ged from a very modest effect in MDAMB468 cells to 2-fold control
with T47D cells when unstimulated in a 7 day period. Factors that
might limit the degree of response include (1) the amount and ra-
tio of FL to D5 Stat5a already present in the cell, and (2) the degree
of growth and survival dependence of each cell line on autocrine
loops and serum factors that utilize Stat5a signaling. However, a
constant feature in the four lines tested was greater cell number
with increased D5 Stat5a. Additional stimulation with PRL further
ampliﬁed this effect in the cell line tested.
4.6. Interactions with b-catenin
Despite the absence of a sequence in the D5 form that is known
to form part of a b-catenin binding site in another protein, both D5
and FL Stat5a bound b-catenin. B-catenin is in large part seques-
tered by E-cadherin at the membrane as part of adherens junctions.
Adherens junctions contribute to contact-inhibition of epithelial
proliferation. While increased expression of both forms of Stat5a
increased levels of E-cadherin, only D5 also increased levels of
b-catenin, thereby increasing the likelihood of free b-catenin in
cells with increased expression of D5 Stat5a. When free from asso-
ciation with E-cadherin, b-catenin can bind to transcription factors
that promote oncogenesis [38]. In the case of FL Stat5a, PRL pro-
moted b-catenin binding, whereas for the D5 form, PRL decreased
b-catenin binding. Thus, assuming that the b-catenin not bound to
the Stat5a forms was in fact free, PRL stimulation in cells express-
ing more D5 Stat5a would be expected to promote cell prolifera-
tion, whereas PRL stimulation in cells expressing more FL Stat5a
may have the opposite effect. However, this prediction remains
to be rigorously tested.
4.7. Primary tumors
The effects on cell number, p21 and Bax expression, induction of
b-catenin, and differential association with multiple transcription
factors are all consistent with a role for D5 Stat5a in tumor pro-
gression, as is the increased expression of D5 Stat5a in invasive
ductal carcinoma of the breast. For the primary tumors, the actual
level of expression varied over a large range. This could be the re-
sult of (1) early splicing changes in regions that were still histolog-
ically normal in some patient samples, and/or (2) inherent
epithelial to stromal variability in composition of samples from
the breast. Nevertheless, a constant feature of cancerous versus
adjacent histologically-normal tissue was an increase in the ratio
of D5 to FL Stat5a.5. Conclusion
While under particular experimental circumstances increased
expression of each form of Stat5a could stimulate b-casein expres-
sion and an increase in cell number, results support the idea that FL
Stat5a is primarily used to promote b-casein expression, whereas
D. Tan et al. / Cancer Letters 346 (2014) 148–157 157the D5 form inhibits this activity and promotes an increase in cell
number. Given these different activity emphases and different
associations with other transcription factors, it is crucial that the
two forms be separately analyzed in future if we are to understand
the role of Stat5a in cancer progression. We propose that inadver-
tent analysis of FL and D5 Stat5a together, and varying ratios of the
two forms in different cell lines used by individual investigators,
may explain some apparently contradictory roles for PRL and
Stat5a activation in breast cancer.
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